Funding Details
- Awarder
- Inbox
- Date Award
- November 01, 2023
- Vertical
- Biotechnology
- Funding URL
- View Funding Page
- Valuation
-
$740,000,000
Company Info
- Traction
- Araris has a pipeline that includes three ADC candidates targeting hematological and solid tumors, with clinical trials expected to begin between 2025 and 2026.
- Organizations Involved
- Taiho Pharmaceutical
- Founders
- Dr. Dragan Grabulovski, Isabella Attinger-Toller, Philipp Spycher
- Company Description
- Araris Biotech is a Swiss biotechnology company known for developing next-generation antibody-drug conjugates (ADCs) through its proprietary platform, AraLinQ™, which improves the design, stability, and manufacturing of ADCs, aiming to offer treatments with better safety profiles and enhanced effectiveness.
- Market
- Oncology
- Location
-
Zurich,
Switzerland
Links